Literature DB >> 35611027

Uremic Optic Neuropathy: A Potentially Reversible Complication of Chronic Kidney Disease.

Niranjan Raja1, Arul Rajagopalan1, Jegan Arunachalam1, Arun Prasath1, Rakesh Durai1, Manorajan Rajendran1.   

Abstract

Uremic optic neuropathy (UON) is one of the rare causes of vision loss in chronic kidney disease patients. It is infrequently seen nowadays as most of the patients are dialyzed early owing to better availability of medical services. It is a clinical diagnosis, correlating loss of vision with optic disc edema in a patient with kidney failure which improves noticeably with hemodialysis and steroids. We describe a patient with UON with excellent improvement on timely institution of hemodialysis and steroid therapy.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Hemodialysis; Steroids; Uremic optic neuropathy

Year:  2022        PMID: 35611027      PMCID: PMC9082141          DOI: 10.1159/000519587

Source DB:  PubMed          Journal:  Case Rep Nephrol Dial


Introduction

Diminution or loss of vision in kidney failure patients can be due to a variety of causes. Uremic optic neuropathy (UON) is one of the rare causes of vision loss in chronic kidney disease patients [1]. It is a clinical diagnosis of exclusion and is usually a presenting feature of uremia with potential reversibility if treatment is instituted early. It is infrequently seen nowadays as most of the patients are dialyzed early owing to better availability of medical services. Unfamiliarity with this condition may lead to a delay in initiating dialysis after the potential period of reversibility which may be futile. Contributing factors to this condition might be uremia with superimposed anemia, hypertension, and malnutrition [1].

Case Report

A 27-year-old male patient presented to the hospital with headache and decreased vision for 3 days with rapid deterioration in a day. There was no history of fever. He had a history of easy fatiguability for the past 6 months, pedal edema, and reduced urine output for the past 2 weeks. He had no comorbidities and was neither a smoker nor an alcoholic. Blood pressure and pulse rate on admission were 190/96 mm Hg and 90 beats/min. Physical examination showed pallor, bilateral pedal edema, and raised jugular venous pulses. He was conscious and oriented. He had no sensory or motor deficit and no neck rigidity. Pupils showed isocoria and sluggish response to light bilaterally, and extraocular movements were normal. Ophthalmic examination revealed a visual acuity of 2/60 and 5/60 in the right eye and left eye, respectively, with a normal field of vision, and color vision was poor in both eyes. Fundoscopy revealed hard exudates over the macula with disc edema in both eyes (shown in Fig. 1).
Fig. 1

Fundus picture. Mild pale edema of the optic disc with hard exudates and narrow retinal vessels in the right and left eye of the patient.

Laboratory investigations revealed a hemoglobin level of 4.7 g/dL, serum creatinine 15.3 mg/dL, and urea 160 mg/dL (Table 1). Urinalysis detected 2+ proteinuria (Table 2). Ultrasonography of the kidneys showed bilateral small-sized kidneys with loss of corticomedullary differentiation. Computed tomography of the brain was a normal study. Anti-nuclear antibody by the immunofluorescence method was negative with normal complement levels. Anti-neutrophil cytoplasmic antibodies serology was also negative. Hepatitis B surface antigen was negative. As the patient was young and did not have a history of hypertension, native kidney disease was attributed to undiagnosed chronic glomerulonephritis, though hypertensive nephrosclerosis could not be ruled out definitely. His blood pressure was controlled gradually with antihypertensives, and hemodialysis was initiated along with steroid therapy and blood transfusion. Three units of packed red blood cells (∼350 mL each) were transfused during dialysis for the first 3 days (1 unit per day). Hemoglobin improved to 8.1 g/dL. Dialysis was conducted daily for the first 3 days and on alternative days for the next 2 weeks and then continued on a thrice-weekly schedule (Table 3). Corticosteroids given were methylprednisolone 500 mg intravenously once daily for 3 days followed by oral prednisolone 1 mg/kg once daily for 1 month followed by tapering for 1 month.
Table 1

Investigations

InvestigationsValuesReference range
Hemoglobin, g/dL4.713.5–17.5
Total count, cells/cumm9,2004.5–13.2
Differential count, %
 Neutrophils6034–71
 Lymphocytes2919–53
 Monocytes75–13
 Eosinophils41–7
Platelets, ×105/mm1.71.5–4
Urea, mg/dL16015–40
Creatinine, mg/dL15.30.5–1.2
Sodium, mEq/L131135–145
Potassium, mEq/L4.13.5–5
Calcium, mg/dL8.18.6–10.3
Phosphate, mg/dL5.53–4.5
Bicarbonate, mEq/L1623–30
Serum albumin, g/dL3.13.4–5.4
Serum globulin, g/dL2.62–3.5
Bilirubin, mg/dL1.30.2–0.8
Direct, mg/dL0.80.1–0.4
Indirect, mg/dL0.40.2–0.7
Alanine aminotransferase, U/L380–40
Aspartate aminotransferase, U/L450–40
Antinuclear antibody (immunofluorescence)NegativeNegative
Complement levels (immunoturbidomentry)
C3, g/dL1.10.9–1.80
C4, g/dL0.30.1–0.40
HIV 1 and HIV 2 antibodiesNonreactiveNonreactive
Hepatitis B surface antigenNegativeNegative
HCV antibodyNegativeNegative
Table 2

Urinalysis

TestResultReference range
Dipstick analysis
ColorYellowYellow
ClarityClearClear
PH7.14.6–8
Specific gravity1.0091.005–1.030
GlucoseNegativeNegative
BloodNegativeNegative
KetoneNegativeNegative
Protein2+Negative
Leukocyte esteraseNegativeNegative
NitrateNegativeNegative
Urine microscopy
White blood cells3–40–5 per high power field
Red blood cells20–4 per high power field
Squamous epithelial cellsNone0–5 per high power field
BacteriaNoneNone
Table 3

Hemodialysis parameters

ParameterFirst sessionSecond sessionSubsequent sessions
Duration, h1.524
Ultrafiltration, L11.52
Blood flow rate, mL/min100150200
Dialysate flow rate, mL/min300500500
FlowCo-currentCounter currentCounter current
Sodium, mEq/L145135135
AnticoagulationHeparin (2500 U)Heparin (5000 U)Heparin (5000 U)
DialyzerFresenius F4Fresenius F6Fresenius F6
On day 2 of dialysis, the patient had a subjective improvement in vision. And, on day 4 after initiation of treatment, visual acuity was 4/60 and 6/60 in the right and left eye, respectively. Fundus showed circumpapillary “high water” line due to improving edema. One month later, the patient's vision improved noticeably, 6/36 and 6/24 in the right eye and left eye, respectively, with brisk pupillary light reflexes.

Discussion

Optic neuropathy in uremia can be categorized etiologically into five main groups [1]; UON, ischemic optic neuropathy, optic neuropathy associated with adverse drug events, optic neuropathy as a consequence of increased intracranial pressure, and optic neuropathy associated with cerebral infection. Ischemic optic neuropathy presents with sudden painless visual loss, optic disc edema, and an altitudinal visual field defect [1]. The visual field defect is nearly pathognomonic of the disease which was not seen in our patient, and it does not improve with dialysis. Affection of vision due to drugs was ruled out as our patient had no medical history. Idiopathic intracranial hypertension, rarely associated with chronic kidney disease patients [2] was ruled out due to a lack of clinical features and imaging findings. Similarly, the patient did not have features of meningitis. The possibility of posterior reversible encephalopathy syndrome (PRES) was considered. Systemic features such as seizures or encephalopathy were absent (though could be a component of uremic encephalopathy if present), and it is unusual for PRES to present with visual loss in the absence of other systemic symptoms [3, 4]. CT brain also did not show any areas with hypointensity. UON is rare and likely an underdiagnosed condition that is potentially reversible. It is a clinical diagnosis, correlating loss of vision with optic disc edema in a patient with kidney failure which improves noticeably with hemodialysis and steroids. Our patient had vision loss as a presenting feature of newly diagnosed renal failure which is quite common in patients of UON though an uncommon presentation of chronic kidney disease [5]. Most of the patients diagnosed with end-stage kidney disease are dialyzed early before the manifestation of severe uremic complications due to better availability of renal replacement therapies. The pathogenesis of UON is not well understood. Nerve conduction studies demonstrate defects in a large number of uremic patients [6]. Evidence of visual system dysfunction is documented by delay in visually evoked potentials with improvement after dialysis [7]. This is believed to be related to uremic toxins like guanidino compounds, myo-inositol, and other middle molecules [8] which may inactivate vitamin-B-dependent enzyme transketolase causing optic nerve dysfunction [9]. Hemodialysis by removing uremic toxins plays a definite role in the treatment of these patients as described by many previous observations [1, 5, 10, 11]. Steroids also seem to be useful in most of these cases. The basis to use steroids is to reduce optic disc edema which is believed to be one of the pathological components of UON. Rapid reduction in edema of the optic disc is warranted as a delay may result in permanent nerve damage. Dialysis helps in reducing optic disc edema directly by reducing volume overload and indirectly by removing uremic toxins. On the other hand, steroids might have an added benefit by their relatively quick and sustained action with regular administration. Knox et al. [12] described 6 patients with diverse causes of vision loss in kidney failure patients and concluded that if correctly diagnosed prompt treatment can reduce morbidity. Lee and Vaithilingam [13] reported a 17-year-old male patient presenting with blurring of vision and ESKD who improved remarkably with steroids and hemodialysis. Korzets et al. [11] reported a patient presenting with diminution of vision in 1 eye with kidney failure, but the patient refused hemodialysis initially; subsequently, he developed UON of the opposite eye in 6 months. Steroids with hemodialysis were instituted after both eyes were involved with dramatic improvement in vision in the second involved eye. Saini et al. [10] reported a patient with acute loss of vision and first-time diagnosed kidney failure who did not respond to steroids, but his vision improved serially with each hemodialysis session. Timing of initiation of treatment may be crucial and may dictate outcomes [1, 11, 12]. It should be considered a medical emergency as the early institution of treatment reduces morbidity [13].

Conclusion

Kidney failure presenting as UON is quite rare. However, vision can be affected by a plethora of conditions in patients with kidney failure. Cognizance of this rare presentation among physicians and nephrologists is necessary as it is potentially reversible with timely hemodialysis and steroid therapy.

Statement of Ethics

The Institutional Ethics Committee (Madurai Medical College) Review Board in our hospital requires approval only for original research and case reports with trial/experimental interventions (procedure/drugs) administered to patients. This patient has not been treated with trial/experimental therapy and has been administered only the approved form of treatment for the condition. All treatment and examinations followed the guidance of the Declaration of Helsinki. Written informed consent for treatment was obtained from the patient. And, written informed consent was obtained from the patient for publication of this case report and accompanying images.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

No financial support was obtained from external sources.

Author Contributions

Dr. Niranjan Raja contributed to initial evaluation, complete follow-up of the patient, and preparation of the manuscript. Prof. Arul Rajagopalan contributed to initial evaluation and preparation of the manuscript. Dr. Jegan Arunachalam contributed to evaluation of the patient. Dr. Arun Prasath contributed to evaluation of the patient. Dr. Rakesh Durai contributed to correction of the manuscript. Prof. Manorajan Rajendran contributed to correction of the manuscript. All authors approved the final manuscript.

Data Availability Statement

All data generated or analyzed during this study are included in this article.
  12 in total

1.  Uremic optic neuropathy.

Authors:  D L Knox; A M Hanneken; F C Hollows; N R Miller; H L Schick; W L Gonzales
Journal:  Arch Ophthalmol       Date:  1988-01

2.  Pattern-reversal visual evoked potentials in patients with chronic renal insufficiency.

Authors:  M Kuba; J Peregrin; F Vít; I Hanusová; J Erben
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1983-11

Review 3.  Optic neuropathy in uremia: an interdisciplinary emergency.

Authors:  W C Winkelmayer; M Eigner; O Berger; W Grisold; C Leithner
Journal:  Am J Kidney Dis       Date:  2001-03       Impact factor: 8.860

4.  Bilateral visual loss: more than meets the eye.

Authors:  Andrew M J Turnbull; Sameer Trikha; Daren Gibson; Anthony R Evans; Rod Foroozan
Journal:  Surv Ophthalmol       Date:  2012-04-28       Impact factor: 6.048

5.  Uremic optic neuropathy. A uremic manifestation mandating dialysis.

Authors:  Z Korzets; E Zeltzer; M Rathaus; R Manor; J Bernheim
Journal:  Am J Nephrol       Date:  1998       Impact factor: 3.754

Review 6.  Peripheral neuropathies associated with chronic renal failure.

Authors:  C F Bolton
Journal:  Can J Neurol Sci       Date:  1980-05       Impact factor: 2.104

7.  Relationship of nervous tissue transketolase to the neuropathy in chronic uremia.

Authors:  R B Sterzel; M Semar; E T Lonergan; G Treser; K Lange
Journal:  J Clin Invest       Date:  1971-11       Impact factor: 14.808

8.  Anterior ischemic optic neuropathy as a complication of hemodialysis.

Authors:  K S Servilla; G C Groggel
Journal:  Am J Kidney Dis       Date:  1986-07       Impact factor: 8.860

9.  Clinical spectrum of reversible posterior leukoencephalopathy syndrome.

Authors:  Vivien H Lee; Eelco F M Wijdicks; Edward M Manno; Alejandro A Rabinstein
Journal:  Arch Neurol       Date:  2008-02

10.  Bilateral optic neuropathy-a rare uraemic manifestation of end-stage renal disease.

Authors:  Kian-Guan Lee; Indralingam Vaithilingam
Journal:  NDT Plus       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.